Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Zolbetuximab Plus Chemo Approaches EU Approval for Advanced Gastric/GEJ Cancer

July 26th 2024

The EMA's CHMP has recommended zolbetuximab plus chemotherapy in select locally advanced unresectable or metastatic HER2-negative gastric or GEJ cancer.

NICE Recommends Pembrolizumab Plus Chemo for Untreated HER2– Advanced Gastric/GEJ Adenocarcinoma

July 26th 2024

NICE recommends pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric or GEJ adenocarcinoma.

Dr Bekaii-Saab on the Ongoing Development of Targeted Therapies in GI Malignancies

July 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses next-generation sequencing and the development of RAS-targeted therapies in gastrointestinal cancers.

Fecal Microbiota Transplants May Enhance Immunotherapy Efficacy in GI Cancers

July 25th 2024

Donor fecal microbiota transplants increased the activity of immunotherapy in patients with GI cancers.

Examining the Evolving 3L Treatment Landscape for mCRC

July 24th 2024

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

July 24th 2024

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

July 24th 2024

Shubham Pant, MD, MBBS, discusses findings from the phase 2b HERIZON-BTC-01 study of zanidatamab in pretreated HER2-positive biliary tract cancer.

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

July 19th 2024

Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC.

Exploring Data Outcomes From the SUNLIGHT Trial

July 17th 2024

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

Factors Driving 3L Therapeutic Selection for mCRC

July 17th 2024

Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).

Dr Kelly on the Role of Ripretinib in the GIST Treatment Paradigm

July 16th 2024

Ciara Kelly, MBBCh, BAO, discusses the current and potential roles for ripretinib in the gastrointestinal stromal tumor treatment paradigm.

Dr Agulnik on the Evolving Management of Heterogenous Disease in GIST

July 16th 2024

Mark Agulnik, MD, discusses the evolving management of heterogeneous disease types in gastrointestinal stromal tumors.

RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC

July 16th 2024

RMC-6236 led to early antitumor activity with an acceptable safety profile in patients with previously treated pancreatic ductal adenocarcinoma.

Innovative Research Continues to Propel Individualized GIST Treatments

July 13th 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.

Dr Trent on The Current Standard of Care and Existing Unmet Needs for Patients with GIST

July 11th 2024

Jonathan C. Trent, MD, PhD discusses the current standard of care and existing unmet needs for patients with GIST.

Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

July 10th 2024

The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.

Exploring Toxicities for Second Line Treatments in mCRC

July 10th 2024

The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.

FDA Approval Sought for Another Formulation of Lutetium Lu 177 Dotatate in SSTR+ GEP-NETs

July 10th 2024

Curium has submitted an NDA to the FDA for its formulation of lutetium Lu 177 dotatate for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer

July 8th 2024

Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.